Literature DB >> 19013626

Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.

Joseph R Francica1, Meghan K Matukonis, Paul Bates.   

Abstract

Ebola virus causes an acute hemorrhagic fever that is associated with high morbidity and mortality. The viral glycoprotein is thought to contribute to pathogenesis, though precise mechanisms are unknown. Cellular pathogenesis can be modeled in vitro by expression of the Ebola viral glycoprotein (GP) in cells, which causes dramatic morphological changes, including cell rounding and surface protein down-regulation. These effects are known to be dependent on the presence of a highly glycosylated region of the glycoprotein, the mucin domain. Here we show that the mucin domain from the highly pathogenic Zaire subtype of Ebola virus is sufficient to cause characteristic cytopathology when expressed in the context of a foreign glycoprotein. Similarly to full length Ebola GP, expression of the mucin domain causes rounding, detachment from the extracellular matrix, and the down-regulation of cell surface levels of beta1 integrin and major histocompatibility complex class 1. These effects were not seen when the mucin domain was expressed in the context of a glycophosphatidylinositol-anchored isoform of the foreign glycoprotein. In contrast to earlier analysis of full length Ebola glycoproteins, chimeras carrying the mucin domains from the Zaire and Reston strains appear to cause similar levels of down-modulation and cell detachment. Cytopathology associated with Ebola glycoprotein expression does not occur when GP expression is restricted to the endoplasmic reticulum. In contrast to a previously published report, our results demonstrate that GP-induced surface protein down-regulation is not mediated through a dynamin-dependent pathway. Overall, these results support a model in which the mucin domain of Ebola GP acts at the cell surface to induce protein down modulation and cytopathic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013626      PMCID: PMC2654768          DOI: 10.1016/j.virol.2008.10.029

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.

Authors:  V E Volchkov; V A Volchkova; E Muhlberger; L V Kolesnikova; M Weik; O Dolnik; H D Klenk
Journal:  Science       Date:  2001-02-01       Impact factor: 47.728

2.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.

Authors:  A Takada; S Watanabe; H Ito; K Okazaki; H Kida; Y Kawaoka
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

3.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

5.  Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis.

Authors:  L Coscoy; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

6.  Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.

Authors:  Stephen Y Chan; Melissa C Ma; Mark A Goldsmith
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

7.  Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells.

Authors:  Matthew R Kasper; Kathleen L Collins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung.

Authors:  Maria Fe Medina; Gary P Kobinger; John Rux; Mehdi Gasmi; David J Looney; Paul Bates; James M Wilson
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

9.  Two retroviral entry pathways distinguished by lipid raft association of the viral receptor and differences in viral infectivity.

Authors:  Shakti Narayan; Richard J O Barnard; John A T Young
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  27 in total

1.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins.

Authors:  Olivier Reynard; Malgorzata Borowiak; Valentina A Volchkova; Sebastien Delpeut; Mathieu Mateo; Viktor E Volchkov
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

3.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

4.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.

Authors:  Lisa A Lopez; Su Jung Yang; Colin M Exline; Srinivas Rengarajan; Kevin G Haworth; Paula M Cannon
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

Review 6.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

7.  Ebolavirus glycoprotein structure and mechanism of entry.

Authors:  Jeffrey E Lee; Erica Ollmann Saphire
Journal:  Future Virol       Date:  2009       Impact factor: 1.831

8.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

Review 9.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

10.  Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol.

Authors:  Moritz Hacke; Patrik Björkholm; Andrea Hellwig; Patricia Himmels; Carmen Ruiz de Almodóvar; Britta Brügger; Felix Wieland; Andreas M Ernst
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.